AbbottABT
ABT
About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Employees: 114,000
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
43% more first-time investments, than exits
New positions opened: 175 | Existing positions closed: 122
22% more call options, than puts
Call options by funds: $1.12B | Put options by funds: $912M
1.03% more ownership
Funds ownership: 77.67% [Q1] → 78.71% (+1.03%) [Q2]
7% more repeat investments, than reductions
Existing positions increased: 1,284 | Existing positions reduced: 1,202
4% more capital invested
Capital invested by funds: $179B [Q1] → $185B (+$6.87B) [Q2]
1% less funds holding
Funds holding: 3,124 [Q1] → 3,103 (-21) [Q2]
17% less funds holding in top 10
Funds holding in top 10: 115 [Q1] → 96 (-19) [Q2]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
3%
upside
Avg. target
$142
8%
upside
High target
$147
12%
upside
8 analyst ratings
6 positive
75%
2 neutral
25%
0 negative
0%
Wells Fargo Lawrence Biegelsen | 8%upside $142 | Overweight Maintained | 18 Jul 2025 |
Raymond James Jayson Bedford | 7%upside $141 | Outperform Maintained | 18 Jul 2025 |
Mizuho Anthony Petrone | 3%upside $135 | Neutral Maintained | 18 Jul 2025 |
Jefferies Matthew Taylor | 10%upside $145 | Buy Upgraded | 18 Jul 2025 |
BTIG Marie Thibault | 10%upside $145 | Buy Maintained | 18 Jul 2025 |
Financial journalist opinion
Based on 21 articles about ABT published over the past 30 days
Neutral
Zacks Investment Research
22 hours ago
NVST or ABT: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?
Positive
Seeking Alpha
1 day ago
Best Dividend Kings: August 2025
Dividend Kings underperformed SPY year-to-date but are showing stronger gains in August, with several stocks achieving double-digit returns in 2025. Fifteen Dividend Kings currently appear undervalued with expected long-term annualized returns of at least 10%, based on Dividend Yield Theory analysis. Recent dividend increases have modestly boosted the group's 2025 dividend growth rate, though it still trails last year's pace.
Positive
The Motley Fool
3 days ago
3 Unstoppable Dividend Stocks to Buy Right Now
How does getting paid to own a stock sound to you? That's exactly what dividends do.
Positive
Zacks Investment Research
6 days ago
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Positive
Zacks Investment Research
1 week ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Positive
Zacks Investment Research
1 week ago
Abbott Gains in Nutrition With Adult Segment Leading Growth
ABT Nutrition unit posts steady gains as adult-focused brands like Ensure and Glucerna drive global demand and market share growth.
Neutral
PRNewsWire
1 week ago
Abbott and Big Ten Conference Rally Students, Alumni, and Fans to Save Lives and Win $1 Million for Their School by Donating Blood This College Football Season
All 18 Big Ten universities will go head-to-head in Year 2 of the nationwide challenge, the 'We Give Blood' drive, to inspire the most blood donations from students, alumni, and fans with the winning school earning $1 million from Abbott for student or community health Abbott is releasing exclusive, limited-edition Homefield designed T-shirts for each Big Ten school. Be among the first to receive one by showing up to donate on 'We Give Blood Day' on Aug. 27 Abbott launched the 'We Give Blood' drive in response to the worst U.S. blood shortages in decades, aiming to inspire the next generation of donors The 2025 winner will be announced at the 2025 Discover Big Ten Football Championship Game on Dec. 6 Anyone eligible can donate blood anywhere across the country anytime from Aug. 27 to Dec. 5 to support their Big Ten school.
Positive
Zacks Investment Research
1 week ago
Abbott Taps Growing TMVR Market With Tendyne System
ABT wins FDA nod for its Tendyne TMVR system, offering a minimally invasive option for patients with severe mitral valve disease.
Positive
Reuters
2 weeks ago
Abbott India's profit climbs on healthy pharmaceutical demand
Drugmaker Abbott India reported an 11.5% rise in first-quarter profit on Tuesday, driven by healthy sales in its mainstay pharmaceuticals segment.
Negative
Seeking Alpha
2 weeks ago
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Abbott's Q2 performance reflects some evenness and the potential headwinds from macroeconomic uncertainties. However, short-term issues like tariffs and drug price control do not fundamentally alter Abbott's long-term moat. As a dividend aristocrat, its fundamental and valuation risks are better gauged by its dividend payouts than accounting EPS.
Charts implemented using Lightweight Charts™